Persistence with teriparatide in patients with osteoporosis: The UK experience

Osteoporosis International

Volumn 17, Issue 11, 2006, Pages 1626-1629

  Arden, N K ^a,b   Earl, S ^b   Fisher, D J ^a   Cooper, C ^a   Carruthers, S ^c   Goater, M ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c Healthcare at Home   (United Kingdom)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Adverse events; Compliance; Osteoporosis; Persistence; Teriparatide

Indexed keywords

PARATHYROID HORMONE[1-34];

AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DATA ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOPOROSIS; PATIENT COMPLIANCE; PERSONAL EXPERIENCE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PATIENT DROPOUTS; SURVIVAL ANALYSIS; TERIPARATIDE;

EID: 33749169801     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-006-0171-5     Document Type: Article

References (12)

1. Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103(2A):12S-17S
2. Bocuzzi SJ, Folz SH, Omar MA, Kahler KH (2005) Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 16(Suppl 3): Abstract OC10
3. Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453-1460
4. McCombs J, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48(3):271-287
5. Cano A (1994) Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 20(2-3):91-99
6. Kotzan JA, Martin BC, Wade WE (1999) Persistence with oestrogen therapy in a postmenopausal Medicaid population. Pharmacotherapy 19(3):363-369
7. NICE (2004) Secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, England, June 2004
8. Sackett DL, Snow JC (1981) Magnitude of compliance and non-compliance. In: Haynes RB, Taylor DW, Sackett DL (eds) Compliance in health care. Johns Hopkins University Press, Baltimore, Maryland, pp 11-23
9. Papaioannou A, Ioannidid G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, Brown J, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14(10):808-813
10. Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89(3):1117-1123
11. Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 14(3):259-262
12. Kelly R, Taggart H (1997) Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ 315 (7117):1235